<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00083759</url>
  </required_header>
  <id_info>
    <org_study_id>ELN100226-RA201</org_study_id>
    <nct_id>NCT00083759</nct_id>
  </id_info>
  <brief_title>Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate</brief_title>
  <official_title>A Phase II, Multicenter, Double-blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Intravenous Natalizumab (300 mg) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Receiving Concomitant Treatment With Methotrexate (MTX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Elan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biogen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability and efficacy of
      natalizumab in subjects diagnosed with moderate to severe rheumatoid arthritis (RA) receiving
      concomitant treatment with methotrexate (MTX). It is thought that natalizumab may stop the
      movement of certain white blood cells, known as lymphocytes, into joint tissue. These cells
      are thought to cause damage in the joints leading to the symptoms of RA.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The biological effect seen with natalizumab was not sufficient to warrant further development
    in RA.
  </why_stopped>
  <start_date>May 2004</start_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>American College of Rheumatology (ACR)20.</measure>
    <time_frame>Month 6</time_frame>
    <description>≥20% reduction from baseline in painful/tender joint count and swollen joint count and ≥20% improvement in at least three of five secondary clinical parameters (e.g., subject global assessment, physician global assessment, pain scale, disability score, and an acute phase reactant)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology (ACR)50</measure>
    <time_frame>Month 6</time_frame>
    <description>≥50% reduction from baseline in painful/tender joint count and swollen joint count and ≥50% improvement in at least three of five secondary clinical parameters (e.g., subject global assessment, physician global assessment, pain scale, disability score, and an acute phase reactant)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology (ACR)70</measure>
    <time_frame>Month 6</time_frame>
    <description>≥70% reduction from baseline in painful/tender joint count and swollen joint count and ≥70% improvement in at least three of five secondary clinical parameters (e.g., subject global assessment, physician global assessment, pain scale, disability score, and an acute phase reactant)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">299</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>natalizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>natalizumab</intervention_name>
    <arm_group_label>natalizumab</arm_group_label>
    <other_name>TYSABRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects will be eligible to begin study participation if they meet all of the following
        inclusion criteria:

          -  Subject is able to read, understand, and voluntarily sign the approved Informed
             Consent form prior to the performance of any study-specific procedures;

          -  Male or female subjects, ≥18 to ≤75 years of age, who has a diagnosis of rheumatoid
             arthritis Functional Class 1 to 3 by the 1987 Revised American Rheumatism Association
             Criteria for the Classification of Rheumatoid Arthritis for at least 6 months prior to
             screening;

          -  Subject is on a stable dose of MTX of at least 10 mg/week for ≥3 months prior to
             randomization (Month 0) without an adequate response;

          -  Female subjects of childbearing potential agree to use adequate, contraceptive methods
             (either intrauterine device [IUD], oral or depot contraceptive, or barrier plus
             spermicide). Female subjects of childbearing potential use adequate contraception for
             at least 2 months prior to study entry and continue contraception for at least 3
             months after their last infusion of study drug;

          -  Subject is willing and able to complete all planned study procedures;

          -  Subject has at least 10 painful/tender and 6 swollen joints at the Month 0 (Baseline)
             visit;

          -  Subject has an elevated CRP level (defined as &gt;2.87 mg/L) at Screening.

        Exclusion Criteria:

        Subjects will be excluded from the study if they meet any of the following exclusion
        criteria:

          -  Subject is pregnant or lactating;

          -  Subject who has experienced an inadequate therapeutic response after at least 3 months
             of treatment with at least one TNF-alpha inhibitor;

          -  Subject who has received treatment with anakinra;

          -  Subject who has received prior treatment with natalizumab;

          -  Subject does not meet the following criteria regarding concomitant medications for RA:

          -  Use of any oral steroid exceeding 10 mg/day of prednisone (or equivalent dose) and not
             administered at a stable dose for at least 1 month prior to randomization (Month 0);

          -  Use of any NSAIDs unless stable for at least 1 month prior to randomization (Month 0);

          -  Use of other anti-arthritic treatments, including approved or experimental oral,
             topical, or injectable biologics or drugs, or devices within 1 month prior to
             randomization (Month 0);

          -  Intra-articular corticosteroid injections within 1 month prior to randomization (Month
             0);

          -  Treatment with any TNF-alpha inhibitor within 2 months prior to randomization (Month
             0);

          -  Subject who is expected to be unavailable for the duration of the trial, likely to be
             noncompliant with the Protocol, or felt to be unsuitable by the Investigator for any
             other reason;

          -  Subject who has a history of a malignancy (other than basal cell carcinoma of the
             skin);

          -  Subject who has a history of clinically significant and/or persistent
             gastrointestinal, pulmonary, chronic infection, cardiovascular, renal, hepatic,
             neurological, dermatological, immunological, major psychiatric (including drug or
             alcohol abusers) or hematological illness, which, in the opinion of the Investigator
             placed the subject at unacceptable risk for participation in the study;

          -  Subject who has any laboratory test at Screening considered significantly abnormal. An
             alanine transaminase (ALT) or aspartate transaminase (AST) ≥1.5 x upper limits of
             normal (ULN) and cytopenia (included any of the following: WBC &lt;3.5 x 1000/uL;
             hemoglobin [Hb] &lt;8 g/dL; platelets &lt;100 x 1000/uL; and/or neutrophils absolute &lt;1.0 x
             1000/uL) were considered significantly abnormal;

          -  Subject who intends to donate blood or blood products during the period of the study
             or within 1 month following completion of the study;

          -  Subject who has a positive tuberculosis (TB) skin test at Screening or within the 30
             days prior to Screening (defined as ≥10 mm induration);

          -  Subject who plans or requires any surgical procedure during the study treatment
             period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Unit / University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Medical Clinic of North County, Inc.</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025-4402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Maine</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Study Group</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Justus Fiechtner, MD, PC</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatic Disease Associates</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Clare's Mercy Hospital</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1C 5B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis Program Research Group Inc.</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 3R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2004</study_first_submitted>
  <study_first_submitted_qc>June 2, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2004</study_first_posted>
  <results_first_submitted>January 27, 2009</results_first_submitted>
  <results_first_submitted_qc>June 1, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2009</results_first_posted>
  <last_update_submitted>July 14, 2016</last_update_submitted>
  <last_update_submitted_qc>July 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Natalizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient entered 24 May 2004, study terminated 28 February 2005. A total of 299 patients were evaluable for safety and 273 patients for efficacy. Study conducted in Argentina, Australia, Canada, Czech Republic, Poland, Slovakia, and the United States.</recruitment_details>
      <pre_assignment_details>Patients who met these criteria were randomized to natalizumab or placebo: aged 18-75 with a diagnosis of rheumatoid arthritis (RA) Functional Class 1-3 for ≥ 6 months, on a stable dose of methotrexate (MTX), having ≥ 10 painful/tender joints, and with elevated C-reactive protein. Stratification based on baseline number of painful/tender joints.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Natalizumab</title>
          <description>Natalizumab 300 mg as monthly IV infusions + methotrexate (MTX)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo IV infusions + methotrexate (MTX)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="150">150 subjects enrolled, 137 (Modified Intention-to-Treat [MITT] Population) for efficacy analyses</participants>
                <participants group_id="P2" count="149">149 subjects enrolled, 136 (Modified Intention-to-Treat [MITT] Population) for efficacy analyses</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inadequate Therapeutic Response</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor's Discretion</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Natalizumab</title>
          <description>Natalizumab 300 mg as monthly IV infusions + methotrexate (MTX)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo IV infusions + methotrexate (MTX)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="137"/>
            <count group_id="B2" value="136"/>
            <count group_id="B3" value="273"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.9" spread="10.5"/>
                    <measurement group_id="B2" value="53.6" spread="10.4"/>
                    <measurement group_id="B3" value="52.3" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Count of Painful/Tender Joints</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>American College of Rheumatology (ACR)20.</title>
        <description>≥20% reduction from baseline in painful/tender joint count and swollen joint count and ≥20% improvement in at least three of five secondary clinical parameters (e.g., subject global assessment, physician global assessment, pain scale, disability score, and an acute phase reactant)</description>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Natalizumab 300 mg as monthly IV infusions + methotrexate (MTX)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo IV infusions + methotrexate (MTX)</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology (ACR)20.</title>
          <description>≥20% reduction from baseline in painful/tender joint count and swollen joint count and ≥20% improvement in at least three of five secondary clinical parameters (e.g., subject global assessment, physician global assessment, pain scale, disability score, and an acute phase reactant)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.089</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>American College of Rheumatology (ACR)50</title>
        <description>≥50% reduction from baseline in painful/tender joint count and swollen joint count and ≥50% improvement in at least three of five secondary clinical parameters (e.g., subject global assessment, physician global assessment, pain scale, disability score, and an acute phase reactant)</description>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Natalizumab 300 mg as monthly IV infusions + methotrexate (MTX)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo IV infusions + methotrexate (MTX)</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology (ACR)50</title>
          <description>≥50% reduction from baseline in painful/tender joint count and swollen joint count and ≥50% improvement in at least three of five secondary clinical parameters (e.g., subject global assessment, physician global assessment, pain scale, disability score, and an acute phase reactant)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.171</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>American College of Rheumatology (ACR)70</title>
        <description>≥70% reduction from baseline in painful/tender joint count and swollen joint count and ≥70% improvement in at least three of five secondary clinical parameters (e.g., subject global assessment, physician global assessment, pain scale, disability score, and an acute phase reactant)</description>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Natalizumab 300 mg as monthly IV infusions + methotrexate (MTX)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo IV infusions + methotrexate (MTX)</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology (ACR)70</title>
          <description>≥70% reduction from baseline in painful/tender joint count and swollen joint count and ≥70% improvement in at least three of five secondary clinical parameters (e.g., subject global assessment, physician global assessment, pain scale, disability score, and an acute phase reactant)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.526</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor will have at least 30 days to request revisions to a proposed Publication. Institution will delete any Confidential Information provided by Sponsor, will delay Publication submission for a further 90 days for the filing of patent applications, and will not issue a press release about the Study without the Sponsor’s prior written consent.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated prematurely on 28 February 2005. The biological effect seen with natalizumab was not sufficient to warrant further development in RA.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Biogen Study Medical Director</name_or_title>
      <organization>Biogen</organization>
      <email>clinicaltrials@biogen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

